Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
de Bono, J. [1 ,2 ]
Bracarda, S. [3 ,4 ]
Chi, K. [5 ]
Massard, C. [6 ]
Olmos Hidalgo, D. [7 ]
Sandhu, S. [8 ]
Sternberg, C. N. [9 ]
Gendreau, S. [10 ]
Xu, N. [11 ]
Baney, T. [12 ]
Maslyar, D. [13 ]
Sweeney, C. J. [14 ]
机构：
[1] Inst Canc Res, Div Clin Studies & Expt Med, London, England
[2] Royal Marsden Hosp, London, England
[3] ITT, Azienda USL Toscana Sud Est, Dept Oncol, Med Oncol, Arezzo, Italy
[4] Osped San Donato, Arezzo, Italy
[5] BC Canc Agcy, Clin Trials Unit, Vancouver, BC, Canada
[6] Inst Gustave Roussy, Early Drug Dev Dept, Villejuif, France
[7] Spanish Natl Canc Res Ctr, Prostate Canc Clin Res Unit, Madrid, Spain
[8] Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[9] San Camillo & Forlanini Hosp, Dept Oncol, Rome, Italy
[10] Genentech Inc, Late Stage Biomarker Dev, San Francisco, CA 94080 USA
[11] Genentech Inc, Biostat Oncol Solid Tumor, San Francisco, CA 94080 USA
[12] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[13] Genentech Inc, Prod Dev Clin Oncol, San Francisco, CA 94080 USA
[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
834TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA plus AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Oudard, S. M.
    Bevans, K. B.
    Attard, G.
    Efstathiou, E.
    Flaig, T. W.
    Franke, F. A.
    Goodman, O. B., Jr.
    De Giorgi, U.
    Pieczonka, C. M.
    Yeruva, K.
    De Porre, P.
    Brookman-May, S. D.
    Dibaj, S.
    Wu, D.
    Mundle, S. D.
    McCarthy, S.
    Steuber, T.
    Suzuki, H.
    Rathkopf, D. E.
    Saad, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S634 - S634
  • [42] A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)
    Szmulewitz, R. Z.
    Posadas, E. M.
    Manchen, B.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
    Kelly, W. K.
    Halabi, S.
    Carducci, M. A.
    George, D. J.
    Mahoney, J. F.
    Stadler, W. M.
    Morris, M. J.
    Kantoff, P. W.
    Monk, J. P., III
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [44] A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)
    Carducci, M.
    Armstrong, A.
    Pili, R.
    Ng, S.
    Huddart, R.
    Agarwal, N.
    Khvorostenko, D.
    Lyulko, O.
    Brize, A.
    Vogelzang, N. J.
    Delva, R.
    Harza, M.
    Thanos, A.
    James, N.
    Werbrouck, P.
    Boegemann, M.
    Hutson, T.
    Milecki, P.
    Nederman, T.
    Sternberg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S713 - S714
  • [45] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials
    Small, E. J.
    Higano, C. S.
    Kantoff, P. W.
    Whitmore, J. B.
    Frohlich, M. W.
    Petrylak, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE).
    Chi, Kim N.
    Rathkopf, Dana E.
    Attard, Gerhardt
    Smith, Matthew Raymond
    Efstathiou, Eleni
    Olmos, David
    Small, Eric Jay
    Lee, Ji Youl
    Ricci, Deborah S.
    Simon, Jason S.
    Zhao, Xin
    Kothari, Nishi
    Cheng, Shinta
    Sandhu, Shahneen Kaur
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
    Paul Monk
    Glenn Liu
    Walter M. Stadler
    Susan Geyer
    Ying Huang
    John Wright
    Miguel Villalona-Calero
    James Wade
    Russell Szmulewitz
    Shilpa Gupta
    Amir Mortazavi
    Robert Dreicer
    Roberto Pili
    Nancy Dawson
    Saby George
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 919 - 926
  • [49] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
    Monk, Paul
    Liu, Glenn
    Stadler, Walter M.
    Geyer, Susan
    Huang, Ying
    Wright, John
    Villalona-Calero, Miguel
    Wade, James
    Szmulewitz, Russell
    Gupta, Shilpa
    Mortazavi, Amir
    Dreicer, Robert
    Pili, Roberto
    Dawson, Nancy
    George, Saby
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 919 - 926
  • [50] Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
    Morris, Michael J.
    Heller, Glenn
    Bryce, Alan Haruo
    Armstrong, Andrew J.
    Beltran, Himisha
    Hahn, Olwen Mary
    McGary, Eric C.
    Mehan, Paul Tracy
    Goldkorn, Amir
    Roth, Bruce J.
    Xiao, Han
    Watt, Colleen
    Hillman, David W.
    Taplin, Mary-Ellen
    Ryan, Charles J.
    Halabi, Susan
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345